Tweetable abstract Findings from a new study of routine clinical practice, throughout the COVID-19 pandemic, including over 400,000 patients from over 800 US hospitals indicates that the benefits of treating patients hospitalized for COVID-19 with remdesivir may extend beyond the hospitalization as it is associated with a 40% reduction in COVID-19 readmissions compared with not initiating remdesivir.
All Keywords
【저자키워드】 COVID-19, Remdesivir, readmission, post-discharge outcomes,
【저자키워드】 COVID-19, Remdesivir, readmission, post-discharge outcomes,